Description

Cadazolid is a synthetic oxazolidinone-class antibacterial agent with a unique chemical structure designed to target serious Gram-positive bacterial infections. Its primary commercial value lies in its development as a potent therapeutic agent for the treatment of Clostridioides difficile infections (CDI), a significant cause of healthcare-associated diarrhea. This product is essential for pharmaceutical R&D laboratories, contract manufacturing organizations (CMOs), and companies developing novel antibiotic formulations, offering a high-purity reference standard and active pharmaceutical ingredient (API) for clinical studies and drug development pipelines.

Application

• Pharmaceutical API Synthesis: Serves as the key active pharmaceutical ingredient (API) in the development and manufacturing of antibiotic drugs targeting CDI.
• Clinical Research & Development: Used as a reference standard in preclinical and clinical trials to evaluate the efficacy, pharmacokinetics, and safety of new Cadazolid-based therapeutics.
• Analytical & Quality Control: Employed as a certified reference material (CRM) in HPLC, LC-MS, and other analytical methods for method validation, impurity profiling, and assay development.
• Antimicrobial Mechanism Studies: Utilized in microbiological research to investigate its unique dual mechanism of action against resistant bacterial strains.
• Formulation Development: Acts as a critical component in the development of various dosage forms, including oral capsules and tablets, for optimal drug delivery.

Basic Information

Product Name	Cadazolid
CAS No.	1025097-10-2
Molecular Formula	C20H21F2N5O4
Molecular Weight	433.41 g/mol
Synonyms	ACT-179811; Cadazolid hydrochloride; (S)-N-[[(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]-1,2-oxazole-5-carboxamide; PF-03709234; Oxazolidinone antibacterial ACT-179811; UNII-0JQ5S7A8QN
EINECS	Contact for details

Quality Control

Our Cadazolid is manufactured under strict quality management systems to ensure it meets the stringent requirements for pharmaceutical intermediates and reference standards. Each batch undergoes comprehensive analytical testing, including HPLC purity, residual solvent analysis, and chiral purity verification. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting compliance with agreed specifications. We support development projects requiring standards aligned with ICH guidelines for stability and impurity profiling.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption, which may affect stability and purity. For long-term storage, consider desiccants or inert atmosphere conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (Chiral HPLC)	≥99.0%
Water Content (KF)	≤1.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.